Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3253
-$0.0868-21.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 97.35% | -55.95% | 39.91% | -10.56% | 44.11% |
| Total Depreciation and Amortization | -- | 0.00% | -50.00% | 0.00% | -75.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,701.08% | -8.82% | -41.04% | -7.49% | -39.29% |
| Change in Net Operating Assets | -402.18% | 232.07% | -60,550.00% | -100.09% | 117.61% |
| Cash from Operations | -139.45% | 55.79% | 0.55% | -538.51% | 87.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 141.41% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | -- |
| Cash from Financing | 126.04% | 161,400.00% | -100.02% | 8,060.76% | -107.91% |
| Foreign Exchange rate Adjustments | 15.69% | -304.00% | 1,766.67% | 83.33% | -105.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.94% | 105.14% | -194.25% | 652.07% | 77.40% |